Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Leukemia.
COG # AALL0434
This study is for patients with newly diagnosed T-cell lymphoblastic leukemia (T-ALL) or T-lineage lymphoblastic lymphoma (T-NHL) stage II-IV.
- Patients with T-ALL must be enrolled on AALL08B1 before treatment on AALL0434 begins.
- Patients with T-NHL are not eligible for AALL08B1 and can enroll directly on to AALL0434.
- Patients must be greater than 1 year and less than 31 years of age.
Mandy Atkinson, M.D.
Wendy McCarty, Clinical Research Coordinator